Bridge Biotherapeutics Rebrands as Parataxis Korea, Shifts Focus to Digital Assets
Bridge Biotherapeutics has rebranded itself as Parataxis Korea, marking a strategic pivot towards a digital asset treasury business. According to NS3.AI, this change comes in the wake of a sale of management rights and a comprehensive business restructuring. The decision follows the unsuccessful development of the company's primary biotech pipeline, prompting a shift in business strategy.
Source: CoinLive The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments